Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging

Exclusion Criteria

• •Pregnant or lactating females
• •Patient with severe immunological diseases and/ or severe acute infectious diseases
• •Patient with heart failure as documented in the medical history or as defined by the investigator during the physical examination performed at visit 1
• •Patient with diagnosis of cancer (except basal cell carcinoma)
• •Patient with a history of depression associated with suicidal ideation or behaviour
• •Patient with moderate or severe hepatic impairment.
• •Patient with lactose intolerance
• •Patient is unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.
• •Patient who received inhalation corticosteroids (ICS) within the last 6 weeks prior to the screening visit
• •Patient who received any investigational new drug within the last 4 weeks prior to the screening visit or twice the duration of the biological effect of any drug (whichever is longer)